Floatz logo

(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine

Breast Carcinoma

Nuvation Bio Inc.Small moleculePhase 1/2Active
C
32/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
17/ 100
Competitive Position
81/ 100

Competitive context

224 Active assets in the Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB

View all 50 →

Same molecule, other indications

(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine is also rated in:

breast neoplasmDormant
C
Indicative ·
32 / 100
View asset →
prostate carcinomaDormant
C
Indicative ·
32 / 100
View asset →
prostate neoplasmDormant
C
Indicative ·
32 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →